## ICMJE DISCLOSURE FORM

| Date:                         | 11/25/2022                                     |
|-------------------------------|------------------------------------------------|
| Your Name:                    | Angelo Hooker                                  |
| Manuscript Title:             | Een bijzondere oorzaak van chronische buikpijn |
| Manuscript Number (if known): | Click or tap here to enter text.               |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |                                                                                                                                                                                                 |                                                    | s/Comments (e.g., if payments were<br>or to your institution) |  |  |  |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------|--|--|--|
|   |                                                                                                                                                                                                 | Time frame: Since the initial planning of the work |                                                               |  |  |  |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. |                                                    | o add additional rows.                                        |  |  |  |
|   | Time frame: past 36 months                                                                                                                                                                      |                                                    |                                                               |  |  |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).                                                                                                            | None                                               |                                                               |  |  |  |
| 3 | Royalties or<br>licenses                                                                                                                                                                        | ☑ None   □ □   □ □                                 |                                                               |  |  |  |

|    |                                                           | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|----|-----------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--|
| 4  | Consulting fees                                           | ⊠ None                                                                                       |                                                                                     |  |
|    |                                                           | Nordic Pharma                                                                                | Presentation of scientific work                                                     |  |
|    |                                                           |                                                                                              |                                                                                     |  |
| 5  | Payment or                                                | □ None                                                                                       |                                                                                     |  |
|    | honoraria for<br>lectures,                                | Nordic Pharma                                                                                | Presentation and speaker on congress                                                |  |
|    | presentations,<br>speakers                                | Merck                                                                                        | Presentation and speaker on congress, sponsoring educational event                  |  |
|    | bureaus,<br>manuscript                                    |                                                                                              |                                                                                     |  |
|    | writing or<br>educational<br>events                       |                                                                                              |                                                                                     |  |
| 6  | Payment for<br>expert testimony                           | ⊠ None                                                                                       |                                                                                     |  |
|    | expert testimony                                          |                                                                                              |                                                                                     |  |
|    |                                                           |                                                                                              |                                                                                     |  |
| 7  | Support for attending                                     | ⊠ None                                                                                       |                                                                                     |  |
|    | meetings and/or<br>travel                                 | Merck<br>Nordic Pharma                                                                       | Support for attending meetings<br>Support for attending meetings                    |  |
|    |                                                           |                                                                                              |                                                                                     |  |
| 8  | Patents planned, X None issued or                         |                                                                                              |                                                                                     |  |
|    | pending                                                   |                                                                                              |                                                                                     |  |
|    |                                                           |                                                                                              |                                                                                     |  |
| 9  | Participation on                                          | □ None                                                                                       |                                                                                     |  |
|    | a Data Safety<br>Monitoring<br>Board or<br>Advisory Board | Nordic Pharma                                                                                | Member of Angel (expert on adhesion prevention_                                     |  |
|    |                                                           | Womed                                                                                        | Member of Safety Monitoring Board                                                   |  |
| 10 | Leadership or                                             | ⊠ None                                                                                       |                                                                                     |  |
|    | fiduciary role in other board,                            |                                                                                              |                                                                                     |  |
|    | society,<br>committee or                                  |                                                                                              |                                                                                     |  |
|    | advocacy group,<br>paid or unpaid                         | ·                                                                                            |                                                                                     |  |

|                                                                                 |                                                                                                 |  | e all entities with whom you have this<br>ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11                                                                              | Stock or stock<br>options                                                                       |  | None                                                                                    |                                                                                     |
| 12                                                                              | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services |  | None                                                                                    |                                                                                     |
| 13                                                                              | Other financial or<br>non-financial<br>interests                                                |  | None                                                                                    |                                                                                     |
| Please place an "X" next to the following statement to indicate your agreement: |                                                                                                 |  |                                                                                         |                                                                                     |